CalciMedica, Inc.
CALCHealthcare|Biotechnology|US
$1.36
+0.06 (+4.62%)
DCF Value
$0.00
Tangible Book / Share
$1.61
Cash / Share
$5.44
Financials
Financial Snapshot
Market Cap
$4.3M
Enterprise Value
-$14.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$21.2M
Cash & Investments
$18.6M
Net Cash
$18.6M
Free Cash Flow (TTM)
-$19.1M
Operating CF (TTM)
-$19.1M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$18.6M
Quarterly Burn
$4.8M
Monthly Burn
$1.6M
Est. Runway
~3.9 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $12.8M | $36.0M | $95.0M | $63.7M | $1.3M | $11.2M | $18.7M | $13.0M | $18.6M | |
| Operating Cash Flow | -$28.2M | -$31.2M | -$32.1M | -$31.5M | -$11.8M | -$25.7M | -$21.1M | -$21.2M | -$19.1M | |
| Free Cash Flow | -$29.7M | -$31.8M | -$33.1M | -$32.0M | -$11.8M | -$25.8M | -$21.2M | -$21.2M | -$19.1M | |
| Capital Expenditure | -$1.5M | -$605.0K | -$1.0M | -$488.0K | -$4.0K | -$78.0K | -$8.0K | -$28.0K | -$14.0K | |
| Financing Cash Flow | $42.0M | $54.9M | $92.2M | $695.0K | $8.5M | $20.9M | $28.0M | $15.2M | $19.6M |
R&D Spending
R&D (TTM)
$12.5M
R&D Intensity
—
R&D Growth vs Prior
-17.7%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $23.0M | $30.6M | $21.0M | $18.9M | $8.3M | $15.9M | $14.5M | $15.2M | $12.5M | |
| SG&A | $5.6M | $6.6M | $8.9M | $17.0M | $5.8M | $22.2M | $9.7M | $7.9M | $7.1M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $175.0K | $303.0K | $395.0K | $519.0K | $0.00 | $0.00 | $0.00 | $46.0K | $7.0K | |
| Gross Profit | -$175.0K | -$303.0K | -$395.0K | -$519.0K | $0.00 | $0.00 | $0.00 | -$46.0K | -$7.0K | |
| R&D | $23.0M | $30.6M | $21.0M | $18.9M | $8.3M | $15.9M | $14.5M | $15.2M | $12.5M | |
| SG&A | $5.6M | $6.6M | $8.9M | $17.0M | $5.8M | $22.2M | $9.7M | $7.9M | $7.1M | |
| Operating Income | -$28.6M | -$37.5M | -$29.8M | -$35.9M | -$14.2M | -$38.1M | -$24.2M | -$23.1M | -$19.6M | |
| Interest Expense | $0.00 | $0.00 | $143.0K | $126.0K | $132.0K | $110.0K | $0.00 | $1.4M | $1.3M | |
| Pretax Income | -$28.4M | -$37.0M | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M | -$21.2M | |
| Net Income | -$28.4M | -$37.0M | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M | -$21.2M | |
| EPS (Diluted) | -165.50 | -179.25 | -367.50 | -118.30 | -116.00 | -38.25 | -6.10 | -9.85 | -6.95 | |
| EBITDA | -$28.2M | -$36.7M | -$27.1M | -$35.3M | -$7.6M | -$34.2M | -$13.6M | -$28.1M | -$19.9M | |
| Shares Out. (M) | 0.17 | 0.21 | 0.09 | 0.30 | 0.31 | 0.90 | 2.25 | 3002.26 | 3.42 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.8M | $15.9M | $33.4M | $13.4M | $1.3M | $5.5M | $7.9M | $11.5M | $18.6M | |
| Short-Term Investments | $0.00 | $20.1M | $61.6M | $50.3M | $0.00 | $5.7M | $10.7M | $1.5M | $0.00 | |
| Total Current Assets | $13.4M | $36.3M | $99.2M | $67.1M | $1.7M | $11.6M | $19.7M | $13.5M | $19.5M | |
| Total Assets | $17.8M | $40.7M | $101.8M | $69.1M | $3.3M | $12.2M | $19.8M | $13.6M | $19.5M | |
| Total Current Liabilities | $5.8M | $12.3M | $7.0M | $4.1M | $4.8M | $4.0M | $3.7M | $3.8M | $3.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $5.2M | $0.00 | $0.00 | $8.4M | $0.00 | |
| Total Liabilities | $5.8M | $12.3M | $7.0M | $4.1M | $12.6M | $4.0M | $5.4M | $20.2M | $14.0M | |
| Stockholders' Equity | $12.0M | $28.4M | $94.8M | $65.0M | -$9.2M | $8.2M | $14.4M | -$6.6M | $5.5M | |
| Retained Earnings | -$68.8M | -$105.8M | -$133.4M | -$169.2M | -$111.7M | -$146.1M | -$159.8M | -$189.3M | -$192.0M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.2M | -$31.2M | -$32.1M | -$31.5M | -$11.8M | -$25.7M | -$21.1M | -$21.2M | -$19.1M | |
| Capital Expenditure | -$1.5M | -$605.0K | -$1.0M | -$488.0K | -$4.0K | -$78.0K | -$8.0K | -$28.0K | -$14.0K | |
| Free Cash Flow | -$29.7M | -$31.8M | -$33.1M | -$32.0M | -$11.8M | -$25.8M | -$21.2M | -$21.2M | -$19.1M | |
| Investing Cash Flow | -$1.5M | -$20.6M | -$42.6M | $10.8M | -$4.0K | $8.9M | -$4.4M | $9.6M | $12.2M | |
| Financing Cash Flow | $42.0M | $54.9M | $92.2M | $695.0K | $8.5M | $20.9M | $28.0M | $15.2M | $19.6M | |
| Issuance of Stock | $42.0M | $0.00 | $96.3M | $695.0K | $18.0K | $25.4M | $28.0M | $5.5M | $16.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $8.5M | $0.00 | $0.00 | $9.7M | $0.00 | |
| Stock Based Comp. | $348.0K | $738.0K | $1.8M | $5.4M | $1.8M | $12.0M | $2.3M | $3.0M | $2.3M | |
| Net Change in Cash | $12.3M | $3.0M | $17.5M | -$20.1M | -$3.3M | $4.1M | $2.4M | $3.6M | $12.7M |
Dilution Tracker
Shares outstanding grew 3175252.7% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+3175252.7%
Stock Issuance (TTM)
$16.6M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.17 | 0.21 | 0.09 | 0.30 | 0.31 | 0.90 | 2.25 | 3002.26 | 3.42 | |
| Change vs Prior % | — | 20.5% | -54.2% | 220.3% | 1.4% | 192.5% | 150.5% | 133382.4% | -99.9% | |
| Stock Issuance | $42.0M | $0.00 | $96.3M | $695.0K | $18.0K | $25.4M | $28.0M | $5.5M | $16.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $348.0K | $738.0K | $1.8M | $5.4M | $1.8M | $12.0M | $2.3M | $3.0M | $2.3M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -236.1% | -130.4% | -29.0% | -55.1% | 84.7% | -421.2% | -95.1% | 445.1% | 3398.4% | |
| ROA % | -159.3% | -91.1% | -27.0% | -51.8% | -233.6% | -282.0% | -69.2% | -217.5% | -108.9% | |
| ROIC % | -237.7% | -132.0% | -31.5% | -55.3% | 1155.8% | -466.8% | -150.2% | -209.1% | -122.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -73.1% | -30.4% | -31.4% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -31.3% | 20.5% | -20.5% | 60.5% | -168.3% | 36.4% | 4.5% | |
| Net Income | 0.0% | -30.5% | 25.7% | -30.1% | 78.2% | -339.1% | 60.1% | -115.8% | |
| EPS (Diluted) | 0.0% | -8.3% | -105.0% | 67.8% | 1.9% | 67.0% | 84.1% | -61.5% | |
| Operating Cash Flow | 0.0% | -10.6% | -2.7% | 1.8% | 62.7% | -118.8% | 17.8% | -0.2% | |
| Free Cash Flow | 0.0% | -7.2% | -4.0% | 3.3% | 63.2% | -119.4% | 18.0% | -0.2% | |
| R&D Expense | 0.0% | 33.1% | -31.5% | -9.8% | -55.8% | 89.9% | -8.7% | 5.2% | |
| SG&A Expense | 0.0% | 18.2% | 34.0% | 92.2% | -65.7% | 280.2% | -56.2% | -18.9% | |
| Total Assets | 0.0% | 128.3% | 150.4% | -32.1% | -95.2% | 263.8% | 62.4% | -31.3% | |
| Book Value / Share | 0.0% | 96.1% | 629.1% | -78.6% | -114.0% | 130.2% | -29.5% | -100.0% | |
| Debt | 0.0% | 66.7% | -100.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 20.5% | -54.2% | 220.3% | 1.4% | 192.5% | 150.5% | 133382.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.84
10Y Low / Med / High0.03 / 0.42 / 2.76
EV/EBITDA0.72
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.00
Tangible Book / Share
$1.61
Net Current Assets / Share
$1.74
Graham Net-Net
$1.35
Cash / Share
$5.44
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.18 | -0.16 | -0.08 | -0.25 | -0.25 | -0.37 | -2.90 | -3.35 | -0.20 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.42 | 0.21 | 0.03 | 0.14 | -0.97 | 1.57 | 2.76 | -14896.04 | 0.84 | |
| EV/EBITDA | -2.52 | -3.31 | 1.13 | 0.13 | -1.70 | -0.21 | -2.34 | -3521.14 | 0.72 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-15.99
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.4M | $6.7M | $3.5M |
| Net Income | -$9.06B | -$15.91B | -$7.43B |
| EPS | $-3.02 | $-5.30 | $-2.48 |
| # Analysts (EPS) | 2 | 2 | 2 |